Today, there are 4 new shares on the Science and Technology Innovation Board for subscription, namely, Heart Pulse Medicine, South Micro Medicine, Hongruan Technology, and Western Superconductor.
These four new shares will be added to The first batch of listing on July 22 。
Historically, the first batch of companies listed on the SME Board and the GEM have achieved very good results at the beginning of listing, bringing huge returns to investors.
As a key project supported by the state, the first batch of listed enterprises have been carefully selected and guaranteed in terms of rules, systems and transactions, We recommend qualified investors to apply for all new shares on today's science and technology innovation board 。
Let's take a look at the relevant information of the four new shares on July 11:
(Note: information, data and pictures are from the prospectus and relevant announcements)
Cardiovascular treatment
Indirect controlling shareholder 0853HK Minimally invasive medical treatment
Cardiovascular Medicine is mainly engaged in the R&D, production and sales of aortic and peripheral vascular interventional medical devices. In the field of aortic interventional medical devices , The company is one of the enterprises with complete product categories, leading scale and market competitiveness in China , The company's main product in this field is aortic covered stent system ; In the field of peripheral vascular interventional medical devices , The company has worked hard for many years , At present, it has peripheral vascular stent system and peripheral vascular balloon dilation Tensioning catheter and other products ; in addition , The company has the only domestic approved and listed intraoperative stent system that can be used in thoracic aortic dissection surgery. 
The main business of the company has not changed significantly since its establishment. After years of development , The company's products have been sold Sold to China thirty Of provinces, autonomous regions and municipalities directly under the Central Government seven hundred Multiple hospitals , And export to South America and other regions. root According to Frost Sullivan one Related research report of , Ranking according to the number of operations applied ,2018 year The company ranks second in the market share of aortic vascular interventional medical devices in China ( The company ranking first is Mayden power ), The market share of domestic brands ranks first 。
Otsuka Holdings, a major shareholder of minimally invasive medicine, is a pharmaceutical holding company listed on the Tokyo Stock Exchange of Japan ( Stock code :4578), It is also one of the largest pharmaceutical enterprises in the world. by two thousand and eighteen year twelve month thirty-one day , Otsuka Holdings share one hundred and sixty-two Subsidiaries , Its business covers pharmaceuticals, nutraceuticals, consumer goods and other diversified businesses. among , The pharmaceutical business focuses on the production of therapeutic drugs related to the central nervous system and oncology , He is also engaged in the vascular system Production of drugs for digestive system, ophthalmology, disease diagnosis, clinical nutrition, etc , And medical device business.
During the reporting period , The company's R&D investment grew steadily , And “ Market demand oriented ” R&D mechanism matching , The main components are as follows : 
The gross profit rate of the company has been at a high level:
Southern Micromedicine
The company is engaged in the R&D, manufacturing and sales of minimally invasive medical devices. At present, the company's main business is to research, develop, produce and sell inspection and minimally invasive surgical instruments used with endoscopes, and equipment and consumables required for microwave ablation. Endoscopic diagnostic and therapeutic instruments are widely used in the clinical diagnosis and treatment of gastrointestinal and respiratory diseases ; oncolytic Equipment and consumables include microwave ablation therapeutic apparatus and microwave ablation needle , Thermal micro cells mainly used for tumor Wave ablation treatment.
The company's core products have competitive advantages. The company's main products include endoscopic minimally invasive diagnostic and therapeutic instruments, tumors Two main product series of ablation equipment , Endoscopic optical coherence tomography system newly developed by the company (EOCT) Acquired the United States FDA approval , In China, this product has entered the innovative medical device of the State Food and Drug Administration Green channel for mechanical approval.
Development of two wheel drive companies in domestic and international markets. Domestic market , The company's endoscopic diagnosis and treatment technology products It has played a strong import substitution role , Effectively reduce the cost of endoscopic diagnosis and treatment , It reduces the burden of patients. company Products sold nationwide 2,900 Multiple hospitals , The coverage rate of top three hospitals has reached 55% above. Foreign market parties noodles , The company has subsidiaries in the United States and Germany , Many products have passed through the United States FDA Ratification and EU CE recognize card , The products are exported to developed countries including the United States, Germany, Canada, Japan, etc seventy Multiple countries And region , It competes with world-class medical device manufacturers.
The main business income of the Company is distributed as follows:
The proportion of R&D expenses of the company is as follows:
One risk tip:
The company is currently involved in two patent lawsuits , Are : Boston Scientific and Boko Instruments The accused product infringes its U.S. Patent No 9,980,725 、 7,094,245 、 8,974,371 Is , Put the issuer And the Issuer's subsidiaries MTU To file a civil action as a defendant in the District Court of Delaware ; Poko Limited subsidiary of the issuer MTE Infringe its European Patent No EP 1 328 199 B1 、 EP 3 023 061 B1 Patent No , In Dusseldorf District Court, Germany MTE And the company's product certification authority SHANGHAI INTERNATIONAL HOLDING CORP. GMBH (EUROPE) Litigation. If the company is finally determined to infringe the patent right involved , The estimated compensation amount range of the company is RMB 2,539.59 RMB 10000 to 4,363.23 Between 10000 yuan , Share in the company two thousand and eighteen The proportion of annual operating income is 2.75% to 4.73% between , Share in the company two thousand and eighteen The proportion of annual net profit is 12.49% to 21.45% between.
Hongruan Technology
Hongruan Technology has always been committed to the R&D and application of visual artificial intelligence technology, adhering to the core driving force of original technology, and providing smart phones $Smart Car Internet of Things（ IoT ）And other intelligent devices Visual AI solutions.
At present, the visual AI solutions provided by the company are mainly used in the smartphone industry, and the main customers include Samsung, Huawei, Xiaomi OPPO , Vivo（ vivo ）、 LG , Sony, Median and other world-famous mobile phone manufacturers. At the same time, the company actively applies visual artificial intelligence technology to $Smart Car , smart home, smart insurance, smart retail, Internet video and other fields to play a positive role in upgrading smart products and related industries.
While maintaining its technological leadership, Hongruan Technology has also launched an AI open platform to share some of Hongruan Technology's core technological achievements, and provided core technologies such as face recognition, ID verification, and live detection for free to enterprises, entrepreneurial teams, and individual developers in need, helping SMEs break technical barriers, Continuously expand the application field of AI vision technology of Hongruan Technology, and accelerate its popularization in various application scenarios.
The main business distribution of Hongruan Technology is as follows:
Western superconductivity
The company is mainly engaged in high-end titanium alloy materials Research and development of superconducting products and high-performance high-temperature alloy materials Production and sales. The company is China's high-end titanium alloy rod and wire One of the main R&D and production bases for forging blanks; At present, it is the only commercial manufacturer of low-temperature superconducting wires in China, and the only full process manufacturer of niobium titanium ingots, superconducting wires and superconducting magnets in the world; It is also one of the key R&D and production enterprises of high-performance superalloy materials in China.
The company's main products include three categories. The first category is high-end titanium alloy materials, including bars, wires and forging blanks; second Class A is a superconducting product, It includes niobium titanium ingot bar, niobium titanium superconducting wire, niobium tristin superconducting wire and superconducting magnet, etc; The third category is high-performance superalloy materials, including deformed superalloys Casting and powder superalloy master alloys, etc. The company's products “ International advanced, domestic blank, urgent need to be solved ” For positioning, Serving the national strategy, It makes up for the urgent need for key materials in the manufacture of new fighters and warships in China “ Short board ” 。
The main business distribution of Western Superconductor is as follows:
